Eli Lilly's COVID-19 Treatment Authorized by the FDA
Eli Lilly (NYSE: LLY) received an emergency use authorization from the Food and Drug Administration for its COVID-19 treatment, bamlanivimab, on Monday afternoon. The drug is a therapeutic antibody designed to bind to the novel coronavirus that causes COVID-19.
The authorization covers patients aged 12 or older who have mild to moderate COVID-19, are at high risk for progressing to severe COVID-19, and might require hospitalization. The FDA would like patients treated as soon as possible after a positive COVID-19 test and certainly within 10 days of the onset of symptoms. The short time frame is going to make it somewhat difficult for doctors to determine which patients are most likely to progress to severe disease.
Image source: Getty Images.
Source Fool.com
